Results 101 to 110 of about 21,508 (266)

Az atópiás dermatitis patomechanizmusa [PDF]

open access: yes, 2018
L
Steuer-Hajdu, Krisztina, Szegedi, Andrea
core   +1 more source

Long‐Term, Site‐Specific Effectiveness of Tralokinumab in Atopic Dermatitis: A 72‐Week Real‐World Study

open access: yesThe Journal of Dermatology, EarlyView.
ABSTRACT Tralokinumab, an anti‐IL‐13 antibody, is effective for atopic dermatitis (AD); however, its long‐term (> 1 year) effectiveness specific to each anatomical site is unknown in real‐world settings. To evaluate 72‐week effectiveness of tralokinumab on different anatomical sites in AD, we studied 208 patients with moderate‐to‐severe AD treated with
Mizuki Shiba   +6 more
wiley   +1 more source

Salivary cytokine panel indicative of non-small cell lung cancer. [PDF]

open access: yes, 2018
Objective To develop a combinatorial panel of salivary cytokines that manifests the presence of non-small cell lung cancer (NSCLC) that will eventually improve prognosis by facilitating the early diagnosis and management of this common cancer. Methods We
Koizumi, Tomonobu   +2 more
core   +3 more sources

Filaggrin-null mutations are associated with increased maturation markers on Langerhans cells [PDF]

open access: yes, 2016
Background Mutations in the gene encoding filaggrin (FLG), an epidermal structural protein, are the strongest risk factor identified for the development of atopic dermatitis (AD).
Andrew J. Muinonen-Martin   +55 more
core   +4 more sources

Sequence of Immunological Events During IgE‐Mediated Allergic Reactions to Food

open access: yesAllergy, EarlyView.
ABSTRACT Food allergies (FA) represent a significant global health burden. Upon allergen re‐exposure, allergic patients exhibit a sequence of symptoms that vary in terms of affected organ systems, severity, time of onset and allergen reactivity thresholds.
N. A. Nagy   +7 more
wiley   +1 more source

A minimally invasive tool to study immune response and skin barrier in children with atopic dermatitis [PDF]

open access: yes, 2019
Background: Atopic dermatitis (AD) affects children of all skin types. Most research has focused on light skin types. Studies investigating biomarkers in people with AD with dark skin types are lacking.
Dontje, B.   +11 more
core   +8 more sources

An 11‐Month‐Old Infant With Unusual Diaper Dermatitis

open access: yes
JEADV Clinical Practice, EarlyView.
Majda Chaoui   +2 more
wiley   +1 more source

Early Risk Assessment and Recognition of Allergies in Children: Rationale, Methodology, and Proposed Algorithms

open access: yesAllergy, EarlyView.
ABSTRACT Background Atopic diseases—including atopic dermatitis (AD), food allergy (FA), allergic rhinitis (AR), and asthma—are the most common chronic conditions in childhood and adolescence, affecting up to 30% of the global population. In Germany alone, more than 2.1 million children and adolescents are affected.
E. Hamelmann   +13 more
wiley   +1 more source

Treatment with Docosahexaenoic Acid Improves Epidermal Keratinocyte Differentiation and Ameliorates Inflammation in Human Keratinocytes and Reconstructed Human Epidermis Models

open access: yesMolecules, 2019
Atopic dermatitis (AD) is a chronic inflammatory skin disease that can cause skin barrier function damage. Although co-incubation with docosahexaenoic acid (DHA) exerts a positive effect on deficient skin models, no studies have investigated the effects ...
Tinghan Jia   +4 more
doaj   +1 more source

Evidence for the critical role of the PI3K signaling pathway in particulate matter-induced dysregulation of the inflammatory mediators COX-2/PGE2 and the associated epithelial barrier protein Filaggrin in the bronchial epithelium

open access: yesCell Biology and Toxicology, 2019
Particulate matter (PM) is an environmental pollutant closely associated with human airway inflammation. However, the molecular mechanisms of PM-related airway inflammation remains to be fully elucidated. It is known that COX-2/PGE2 play key roles in the
Chenjian Song   +8 more
semanticscholar   +1 more source

Home - About - Disclaimer - Privacy